Search Result

Pathways Recommended:	Neuronal Signaling Cell Cycle/DNA Damage

Results for "

neuronal damage

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (2) Adrenergic Receptor (2) Akt (1) Amyloid-β (2) Apoptosis (7) ATF6 (1) Autophagy (2) Calcium Channel (1) CaMK (1) COX (1) Dopamine Receptor (2) Endogenous Metabolite (6) Ferroptosis (1) Glutathione Peroxidase (1) iGluR (3) Isotope-Labeled Compounds (1) Keap1-Nrf2 (2) mAChR (2) Mitophagy (2) Na+/Ca2+ Exchanger (3) nAChR (1) Necroptosis (1) NO Synthase (4) p38 MAPK (1) Phosphodiesterase (PDE) (3) PI3K (1) RAR/RXR (1) Reactive Oxygen Species (3) Serotonin Transporter (1) Transferrin Receptor (1) TRP Channel (1) α-synuclein (2)
By Research Areas:	Cancer (4) Cardiovascular Disease (5) Infection (1) Inflammation/Immunology (9) Metabolic Disease (4) Neurological Disease (39)

By Targets:

5-HT Receptor (2)

Adrenergic Receptor (2)

Akt (1)

Amyloid-β (2)

Apoptosis (7)

ATF6 (1)

Autophagy (2)

Calcium Channel (1)

CaMK (1)

COX (1)

Dopamine Receptor (2)

Endogenous Metabolite (6)

Ferroptosis (1)

Glutathione Peroxidase (1)

iGluR (3)

Isotope-Labeled Compounds (1)

Keap1-Nrf2 (2)

mAChR (2)

Mitophagy (2)

Na+/Ca2+ Exchanger (3)

nAChR (1)

Necroptosis (1)

NO Synthase (4)

p38 MAPK (1)

Phosphodiesterase (PDE) (3)

PI3K (1)

RAR/RXR (1)

Reactive Oxygen Species (3)

Serotonin Transporter (1)

Transferrin Receptor (1)

TRP Channel (1)

α-synuclein (2)

By Research Areas:

Cancer (4)

Cardiovascular Disease (5)

Infection (1)

Inflammation/Immunology (9)

Metabolic Disease (4)

Neurological Disease (39)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155126

LZWL02003	Reactive Oxygen Species	Neurological Disease
LZWL02003 is an anti-neuroinflammatory agent. LZWL02003 has protective effect on MPP ⁺-induced neuronal damage, and reduces the expression of ROS. LZWL02003 improves cognition, memory, learning, and athletic ability in a Rotenone (HY-B1756)-induced PD rat model. LZWL02003 can be used for research of neurodegenerative disease .

HY-N6669

Methyl 3-O-methylgallate 1 Publications Verification M3OMG	Others	Neurological Disease
Methyl 3-O-methylgallate (M3OMG) possesses antioxidant effect and can protect neuronal cells from oxidative damage .

HY-120875

HX600	RAR/RXR	Neurological Disease
HX600 is a synthetic agonist for RXR (Retinoid X Receptor) heterodimer complex. HX600 prevents ischemia-induced neuronal damage. HX600 has orally bioactivity .

HY-108038

ABT-107	nAChR	Neurological Disease
ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions .

HY-100807

Quinolinic acid 4 Publications Verification	Endogenous Metabolite iGluR	Neurological Disease Inflammation/Immunology
Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-P5883

TAT-M2NX tatM2NX	TRP Channel	Neurological Disease
TAT-M2NX (tatM2NX) is a TRPM2 inhibitor with specific neuroprotective activity in male mice. TAT-M2NX can be used to study ischemic neuronal damage .

HY-P3780

Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42)	Amyloid-β	Neurological Disease
Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment .

HY-111499

Emopamil	Endogenous Metabolite Calcium Channel	Neurological Disease
Emopamil is an inhibitor of calcium channel that can reduce ischemia-induced neuronal cell damage .

HY-N10283

Neoechinulin C	Endogenous Metabolite	Neurological Disease
Neoechinulin C, an echinulin-related indolediketopiperazine alkaloid, protects the neuronal cells against paraquat-induced damage in a Parkinson’s disease model .

HY-162385

COX-2-IN-42	COX	Inflammation/Immunology
COX-2-IN-42 (Compound T1) is a COX-2 inhibitor, and protects zebrafish against PTZ-induced neuronal damage .

HY-N4098

Incensole Acetate	Apoptosis	Neurological Disease
Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs .

HY-113772

Inflachromene	Others	Neurological Disease Inflammation/Immunology
Inflachromene, a microglial inhibitor, binds to HMGB1 and HMGB2 and exerts anti-inflammatory effects. Inflachromene effectively downregulates proinflammatory functions of HMGB and reduces neuronal damage. Inflachromene can be used for the research of neuroinflammatory disorders .

HY-133712

Yonkenafil Tunodafil	Phosphodiesterase (PDE)	Neurological Disease
Yonkenafil (Tunodafil), a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .

HY-100807S2

Quinolinic acid-13C4,15N	Endogenous Metabolite	Neurological Disease Inflammation/Immunology
Quinolinic acid-13C4, 15N is an isotopic labeled Quinolinic acid (HY-100807). Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist and has the potential of mediating NMDA neuronal damage and dysfunction .

HY-125095

Yonkenafil hydrochloride Tunodafil hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease Neurological Disease
Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease .

HY-120553

B-355252	Apoptosis	Neurological Disease
B355252, a phenoxy thiophene sulfonamide small molecule, is a potent NGF receptor agonist. B355252 potentiates NGF-induced neurite outgrowth. B355252 protects ischemic neurons from neuronal loss by attenuating DNA damage, reducing ROS production and the LDH level, and preventing neuronal apoptosis. B355252 has anti-apoptotic effects in glutamate-induced excitotoxicity, as well as in a murine hippocampal cell line (HT22) model of Parkinson disease (PD) .

HY-14314

ABT-418	Endogenous Metabolite	Neurological Disease
ABT-418 is a selective neuronal nicotinic acetylcholine receptor ligand with activity in improving spatial memory. ABT-418 administered before training can significantly reduce the spatial discrimination deficit caused by ventricular damage. ABT-418 is considered to be a potential treatment for attention deficit disorder .

HY-100807R

Quinolinic acid (Standard) 4 Publications Verification	Endogenous Metabolite iGluR	Neurological Disease Inflammation/Immunology
Quinolinic acid (Standard) is the analytical standard of Quinolinic acid. This product is intended for research and analytical applications. Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-N4098R

Incensole Acetate (Standard)	Apoptosis	Neurological Disease
Incensole Acetate (Standard) is the analytical standard of Incensole Acetate. This product is intended for research and analytical applications. Incensole acetate is a main constituent of Boswellia carterii resin, has neuroprotective effects against neuronal damage in traumatic and ischemic head injury. Incensole acetate reduces Aβ25–35-triggered apoptosis in hOBNSCs .

HY-100807S1

Quinolinic acid-13C7	Isotope-Labeled Compounds	Others
Quinolinic acid- ¹³C₇is the ¹³C labeledQuinolinic acid(HY-100807) . Quinolinic acid is an endogenous N-methyl-D-aspartate (NMDA) receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction .

HY-118700

2-Iminobiotin Guanidinobiotin	NO Synthase	Neurological Disease
2-Iminobiotin (Guanidinobiotin) is a biotin (vitamin H or B7) analog. 2-Iminobiotin is a reversible nitric oxide synthases inhibitor with K_is of 21.8 and 37.5μM for murine iNOS and rat n-cNOS, respectively . 2-Iminobiotin superimposes on hypothermia protects human neuronal cells from hypoxia-induced cell damage .

HY-107343

Docosahexaenoic acid ethyl ester Ethyl docosahexaenoate	Others	Neurological Disease Metabolic Disease
Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) is a 90% concentrated ethyl ester of docosahexaenoic acid manufactured from the microalgal oil. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Docosahexaenoic acid (DHA) is a key component of the cell membrane, and its peroxidation is inducible due to the double-bond chemical structure. Docosahexaenoic acid has neuroprotective effects .

HY-P10360

Tat-βsyn-degron	α-synuclein	Neurological Disease
Tat-βsyn-degron is an α-synuclein knockdown peptide. Tat-βsyn-degron binds toα-synuclein and reduces α-synuclein levels in primary rat cortical neuron cultures. Tat-βsyn-degron also reduces α-synuclein levels and decreases the parkinsonian toxin-induced neuronal damage and motor impairment in a mouse toxicity model of PD .

HY-N6967

Levomenol (-)-α-Bisabolol	Apoptosis	Neurological Disease Inflammation/Immunology
Levomenol ((-)-α-Bisabolol), a monocyclic sesquiterpene alcohol, exerts antioxidant, anti-inflammatory, and anti-apoptotic activities. Levomenol also has neuroprotective effects and prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice. Levomenol attenuates nociceptive behaviour and central sensitisation in a rodent model of trigeminal neuropathic pain. Orally active .

HY-B1142

Lipoamide 5+ Cited Publications (±)-α-Lipoamide; DL-Lipoamide; DL-6,8-Thioctamide	NO Synthase	Others
Lipoamide ((±)-α-Lipoamide) is a monocarboxylic acid derivative of a neutral amide, formed by the condensation of the carboxyl group of lipoic acid and ammonia. Lipoamide protects against oxidative stress-mediated neuronal cell damage and also acts as a coenzyme to transfer acetyl groups and hydrogen during pyruvate deacylation. Lipoamide also stimulates mitochondrial biogenesis in adipocytes through the endothelial NO synthase-cGMP-protein kinase G signaling pathway .

HY-118700A

2-Iminobiotin hydrobromide Guanidinobiotin hydrobromide	NO Synthase	Neurological Disease
2-Iminobiotin hydrobromide (Guanidinobiotin hydrobromide) is a biotin (vitamin H or B7) analog. 2-Iminobiotin hydrobromide is a reversible nitric oxide synthases inhibitor with K_is of 21.8 and 37.5 μM for murine iNOS and rat n-cNOS, respectively . 2-Iminobiotin hydrobromide superimposes on hypothermia protects human neuronal cells from hypoxia-induced cell damage .

HY-P99797

Pabinafusp alfa JR-141	Transferrin Receptor	Neurological Disease
Pabinafusp alfa (JR-141) is a transferrin receptor-targeting antibody consisting of Iduronate 2-sulfatase (HY-P76399) and an anti-human transferrin receptor antibody. Pabinafusp alfa is blood-brain permeable and prevents heparan sulfate (HS) deposition in the central nervous system of mucopolysaccharidosis II (MPS II) mice. Pabinafusp alfa improves learning and prevents central nervous system neuronal damage in mice .

HY-111093

Protein kinase inhibitor 8	CaMK	Neurological Disease
Protein kinase inhibitor 8 (Compound CK59) is a calmodulin-dependent protein kinase II (CaMKII) inhibitor. By inhibiting the activity of CaMKII, Protein kinase inhibitor 8 can attenuate the cytotoxicity induced by perfluorooctane sulfonic acid (PFOS) and alleviate the downregulation of GLT-1 expression caused by PFOS, thereby reducing neuronal damage. Protein kinase inhibitor 8 may be useful in research related to neurodegenerative diseases .

HY-125039

N-Acetyl lysyltyrosylcysteine amide 2 Publications Verification	Glutathione Peroxidase	Cardiovascular Disease Neurological Disease
N-Acetyl lysyltyrosylcysteine amide is a potent, reversible, specific, and non-toxic tripeptide inhibitor of myeloperoxidase (MPO). N-Acetyl lysyltyrosylcysteine amide effectively inhibits MPO generation of toxic oxidants in vivo. N-Acetyl lysyltyrosylcysteine amide reduces neuronal damage and preserves brain tissue and neurological function in the stroked brain. N-Acetyl lysyltyrosylcysteine amide inhibits MPO-dependent hypochlorous acid (HOCl) generation, protein nitration, and LDL oxidation .

HY-124293

AA147 3 Publications Verification	ATF6 Reactive Oxygen Species	Neurological Disease Metabolic Disease
AA147 is a endoplasmic reticulum (ER) proteostasis regulator. AA147 promotes protection against oxidative damage in neuronal cells and prevents endothelial barrier dysfunction by activating ATF6 arm (selectively) of the unfolded protein response (UPR) and the NRF2 oxidative stress response. AA147 can rebalances XBP1s expression in vivo, and also induces survival motor neuron (SMN) expression and spinal motorneuron (MN) protection .

HY-N6967R

Levomenol (Standard)	Apoptosis	Neurological Disease Inflammation/Immunology
Levomenol (Standard) is the analytical standard of Levomenol. This product is intended for research and analytical applications. Levomenol ((-)-α-Bisabolol), a monocyclic sesquiterpene alcohol, exerts antioxidant, anti-inflammatory, and anti-apoptotic activities. Levomenol also has neuroprotective effects and prevents neuronal damage and memory deficits through reduction of proinflammatory markers induced by permanent focal cerebral ischemia in mice. Levomenol attenuates nociceptive behaviour and central sensitisation in a rodent model of trigeminal neuropathic pain. Orally active .

HY-107343R

Docosahexaenoic acid ethyl ester (Standard)	Others	Neurological Disease Metabolic Disease
Docosahexaenoic acid ethyl ester (Standard) is the analytical standard of Docosahexaenoic acid ethyl ester. This product is intended for research and analytical applications. Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) is a 90% concentrated ethyl ester of docosahexaenoic acid manufactured from the microalgal oil. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Docosahexaenoic acid (DHA) is a key component of the cell membrane, and its peroxidation is inducible due to the double-bond chemical structure. Docosahexaenoic acid has neuroprotective effects .

HY-146619

RAGE/SERT-IN-1	Amyloid-β Serotonin Transporter	Neurological Disease
RAGE/SERT-IN-1 is a potent and orally active advanced glycation end products (RAGE) and serotonin transporter (SERT) inhibitor with IC₅₀s of 8.26 μM and 31.09 nM, respectively. RAGE/SERT-IN-1 exhibits significant neuroprotective effect against Aβ_25-35-induced neuronal damage and alleviates depressive behavior of mice. RAGE/SERT-IN-1 can be used for researching the comorbidity of Alzheimer's disease and depression .

HY-14541

Olanzapine 5+ Cited Publications LY170053	5-HT Receptor Dopamine Receptor mAChR Adrenergic Receptor Autophagy Mitophagy Apoptosis	Neurological Disease Cancer
Olanzapine (LY170053) is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (K_i=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (K_i=11 to 31 nM), muscarinic M1-5 (K_i=1.9-25 nM), and adrenergic α1 receptor (K_i=19 nM). Olanzapine is an atypical antipsychotic .

HY-14541A

Olanzapine hydrochloride LY170053 hydrochloride	5-HT Receptor Dopamine Receptor mAChR Adrenergic Receptor Autophagy Mitophagy Apoptosis	Neurological Disease Cancer
Olanzapine hydrochloride is a selective, orally active monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (K_i=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (K_i=11 to 31 nM), muscarinic M1-5 (K_i=1.9-25 nM), and adrenergic α1 receptor (K_i=19 nM). Olanzapine hydrochloride is an atypical antipsychotic .

HY-163151

JE-133	PI3K Akt p38 MAPK	Neurological Disease Inflammation/Immunology
JE-133 is an optically active isochromane-2H-chromene conjugate. JE-133 exhibits antioxidant and anti-inflammatory activities. JE-133 is a neuroprotective agent that effectively inhibits neuronal oxidative damage associated with PI3K/Akt and MAPK signaling pathways. JE-133 can also inhibit lipopolysaccharide (LPS) (HY-D1056)-induced neuroinflammation by regulating JAK/STAT and Nrf2 signaling pathways .

HY-159152

PQM-164	Reactive Oxygen Species α-synuclein Keap1-Nrf2	Neurological Disease
PQM-164 (Compound 3e) has antioxidant activity (IC₅₀: 0.93 μM for DPPH radical). PQM-164 shows anti-inflammatory activity against 6-OHDA (HY-B1081A)-induced neuronal damage in activated microglial cells. PQM-164 decreases the accumulation of α-synuclein. PQM-164 promotes nuclear translocation of Nrf2 and its transcriptional activity. PQM-164 can be used for research of Parkinson’s disease .

HY-136182

YM-244769 dihydrochloride	Na+/Ca2+ Exchanger	Cardiovascular Disease Neurological Disease
YM-244769 dihydrochloride is a potent, selective and orally active Na ⁺/Ca ²⁺ exchanger (NCX) inhibitor. YM-244769 dihydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca ²⁺ entry mode), with IC₅₀s of 18 nM and 50 nM, respectively. YM-244769 dihydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 dihydrochloride can also increase urine volume and urinary excretion of electrolytes in mice .

HY-136182A

YM-244769	Na+/Ca2+ Exchanger	Cardiovascular Disease Neurological Disease
YM-244769 is a potent, selective and orally active Na ⁺/Ca ²⁺ exchanger (NCX) inhibitor. YM-244769 preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca ²⁺ entry mode), with IC₅₀s of 18 nM and 50 nM, respectively. YM-244769 efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 can also increase urine volume and urinary excretion of electrolytes in mice .

HY-107659

YM-244769 hydrochloride	Na+/Ca2+ Exchanger	Cardiovascular Disease Neurological Disease
YM-244769 hydrochloride is a potent, selective and orally active Na ⁺/Ca ²⁺ exchanger (NCX) inhibitor. YM-244769 hydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca ²⁺ entry mode), with IC₅₀s of 18 nM and 50 nM, respectively. YM-244769 hydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 hydrochloride can also increase urine volume and urinary excretion of electrolytes in mice .

HY-14909

Bardoxolone Maximum Cited Publications 15 Publications Verification CDDO; RTA 401	Keap1-Nrf2 Necroptosis	Metabolic Disease Cancer
Bardoxolone (RTA 401; CDDO) is a novel nuclear regulatory factor (NRf-2) activator. Bardoxolone is a potent necroptosis inhibitor that inhibits Z-VAD-FMK-induced necroptosis. Bardoxolone methyl enhances the antioxidant system, modulates inflammatory cytokines and inhibits apoptosis in rat kidney, demonstrating inhibition on APAP-induced acute kidney injury (AKI) and analgesic effect. Additionally, Bardoxolone methyl decreases Paclitaxel (PAC) (HY-B0015)-induced mitochondrial damage in neuronal cells. Bardoxolone methyl is promising for the research of chemotherapy-induced neuropathic pain and chronic kidney disease .

HY-N1860

3-O-Methylquercetin	Phosphodiesterase (PDE) NO Synthase	Infection Neurological Disease Inflammation/Immunology
3-O-Methylquercetin is an inhibitor of cAMP and CGMP-phosphodiesterase (PDE) with IC₅₀ at 13.8 μM and 14.3 μM, respectively. 3-O-Methylquercetin is an inhibitor of β-secretase with an IC₅₀ of 6.5 μM. 3-O-Methylquercetin has a neuroprotective effect against neuronal death caused by oxidative damage. 3-O-Methylquercetin has strong antiviral activity against poliovirus, coxsackie virus and human rhinovirus. 3-O-Methylquercetin has anti-inflammatory and trachea-relaxing effects and can be used in the study of inflammatory diseases and asthma .

HY-145858

Chalcones A-N-5	Ferroptosis	Cancer
Chalcones A-N-5 is a trihydroxy chalcone derivative compound. Chalcones A-N-5 doesn’t show cytotoxicity at the concentration lower than 100 µM (with IC₅₀ > 1 mM), but has a significant effect on promoting cell proliferation. Chalcones A-N-5 potentially promotes neuronal cell growth in the damaged brain tissue. Chalcones A-N-5 also inhibits ferroptosis induced by RSL or erastin and reduces the lipid peroxidation levels induced by Aβ1-42 protein aggregation. Chalcones A-N-5 is a promising molecular skeleton candidate for further development of lead compound for in vivo test to research AD .

HY-12882

Ifenprodil RC 61-91; NP-120	iGluR	Neurological Disease
Ifenprodil (RC 61-91) is a noncompetitive NMDA receptor antagonist with anti-excitotoxic activity. Ifenprodil significantly improves long-term sensorimotor and spatial learning deficits in mice after acute subarachnoid hemorrhage. Ifenprodil reduces neuronal cell death in the basal cortex and CA1 region of the hippocampus induced by experimental subarachnoid hemorrhage. Ifenprodil attenuates Ca2+ overload in basal cortical cells and mitochondria, as well as brain edema in blood-brain barrier damage and early brain injury. Ifenprodil reduces the intracellular Ca2+ increase and apoptosis of primary cortical neurons under conditions of high glutamate concentrations. Ifenprodil also reduces the increase in endothelial permeability caused by high glutamate concentrations in human brain microvascular endothelial cells. Ifenprodil also inhibits GIRK channels and interacts with α1-adrenergic, 5-HT, and σ receptors .

Cat. No.	Product Name	Target	Research Area